Cosmo Pharmaceuticals NV (CHIX:COPNZ) COGS-to-Revenue : 0.43 (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Cosmo Pharmaceuticals NV COGS-to-Revenue?

Cosmo Pharmaceuticals NV's Cost of Goods Sold for the six months ended in Jun. 2023 was CHF18.4 Mil. Its Revenue for the six months ended in Jun. 2023 was CHF42.6 Mil.

Cosmo Pharmaceuticals NV's COGS to Revenue for the six months ended in Jun. 2023 was 0.43.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Cosmo Pharmaceuticals NV's Gross Margin % for the six months ended in Jun. 2023 was 56.78%.

Cosmo Pharmaceuticals NV COGS-to-Revenue Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV COGS-to-Revenue Chart

Cosmo Pharmaceuticals NV Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

Get a 7-Day Free Trial

0.11

0.15

0.17

0.23

0.18

Cosmo Pharmaceuticals NV Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
COGS-to-Revenue	Get a 7-Day Free Trial															0.49	0.04	0.41	0.03	0.43

Cosmo Pharmaceuticals NV COGS-to-Revenue Calculation

Cosmo Pharmaceuticals NV's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	18.516	/	100.748
	=	0.18

Cosmo Pharmaceuticals NV's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	18.409	/	42.592
	=	0.43

Cosmo Pharmaceuticals NV (CHIX:COPNz) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Cosmo Pharmaceuticals NV's Gross Margin % for the six months ended in Jun. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	18.409 / 42.592
	=	56.78 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cosmo Pharmaceuticals NV COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (CHIX:COPNz) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

CMOPF:USA C43:Germany COPN:Switzerland

Address

Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2

Website

https://www.cosmopharma.com

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Headlines

No Headlines